{"id":"NCT02550288","sponsor":"Organon and Co","briefTitle":"A Clinical Trial to Assess the Efficacy and Safety of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-383)","officialTitle":"A Phase III, Randomized, Active Comparator-controlled Clinical Trial to Study the Efficacy and Safety of MK-0653C in Japanese Patients With Hypercholesterolemia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-09-29","primaryCompletion":"2016-05-30","completion":"2016-05-30","firstPosted":"2015-09-15","resultsPosted":"2017-06-21","lastUpdate":"2024-05-16"},"enrollment":309,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Hypercholesterolemia"],"interventions":[{"type":"DRUG","name":"Ezetimibe 10 mg","otherNames":[]},{"type":"DRUG","name":"Atorvastatin 10 mg","otherNames":[]},{"type":"DRUG","name":"Placebo for Ezetimibe 10 mg tablet","otherNames":[]},{"type":"DRUG","name":"Placebo for Atorvastatin 10 mg capsule","otherNames":[]},{"type":"BEHAVIORAL","name":"Diet control/Daily Exercise","otherNames":[]}],"arms":[{"label":"Ezetimibe 10 mg","type":"ACTIVE_COMPARATOR"},{"label":"Atorvastatin 10 mg","type":"ACTIVE_COMPARATOR"},{"label":"Atorvastatin 20 mg","type":"ACTIVE_COMPARATOR"},{"label":"Ezetimibe 10 mg + Atorvastatin 10 mg","type":"EXPERIMENTAL"},{"label":"Ezetimibe 10 mg + Atorvastatin 20 mg","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the efficacy and safety of MK-0653C (Ezetimibe \\[EZ\\] 10 mg/Atorvastatin \\[Atora\\] 10mg or 20 mg) compared to EZ 10 mg, Atora 10 mg, or Atora 20 mg alone when administered to Japanese participants with hypercholesterolemia. The primary hypothesis is that MK-0653C (EZ 10 mg/Atorva 10 mg) is superior to EZ 10 mg and is superior to Atorva 10 mg and that MK-0653C (EZ 10 mg/Atorva 20 mg) is superior to EZ 10 mg and is superior to Atorva 20 mg in percent change from baseline in low-density lipoprotein cholesterol (LDL-C) after 12 weeks of treatment.","primaryOutcome":{"measure":"Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12","timeFrame":"Baseline and Week 12","effectByArm":[{"arm":"Ezetimibe 10 mg","deltaMin":-19.3,"sd":null},{"arm":"Atorvastatin 10 mg","deltaMin":-44,"sd":null},{"arm":"Atorvastatin 20 mg","deltaMin":-49.1,"sd":null},{"arm":"Ezetimibe 10 mg + Atorvastatin 10 mg","deltaMin":-55.6,"sd":null},{"arm":"Ezetimibe 10 mg + Atorvastatin 20 mg","deltaMin":-59.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG003","p":"<0.001"},{"comp":"OG001 vs OG003","p":"<0.001"},{"comp":"OG000 vs OG004","p":"<0.001"},{"comp":"OG002 vs OG004","p":"<0.001"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":15},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":35},"commonTop":["Nasopharyngitis","Alanine aminotransferase increased"]}}